Confo Therapeutics is awarded € 2.6 million in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology
Ghent, Belgium: 1 February 2017 - Confo Therapeutics, an emerging drug discovery company, today announced that it has received a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). Confo Therapeutics will use the grant, which has a duration of 2 years and which will mostly be allocated to the Company's Drug Discovery Center in Gent, to discover new GPCR agonist compounds for the treatment of fibrosis.
Last month, through its Target Discovery Center in Brussels, the Company was also awarded a €0.97 million grant from Innoviris, the Brussels Institute for the encouragement of scientific research and innovation, to further broaden the applicability of its proprietary Confo® technology.
More info on Confo Therapeutics' website.
Next > Partnership initiated for the development of a Wood to Chemicals Reference Plant in Delfzijl
Previous > Mainstay Medical starts commercialization of ReActiv8® for the treatment of Chronic Low Back Pain